.
.
.
.
Coronavirus

New Zealand links 26-year-old man’s death to Pfizer COVID-19 vaccine

Published: Updated:

New Zealand authorities on Monday said they had linked a 26-year-old man’s death to Pfizer Inc’s COVID-19 vaccine after the person suffered myocarditis, a rare inflammation of the heart muscle, after taking his first dose.

The death is New Zealand’s second linked to a known but rare side effect from the vaccine after health authorities in August reported a woman had died after taking her doses.

For more coronavirus news, visit our dedicated page.

“With the current available information, the board has considered that the myocarditis was probably due to vaccination in this individual,” a COVID-19 Vaccine Independent Safety Monitoring Board said in a statement.

The man, who died within two weeks of his first dose, had not sought medical advice or treatment for his symptoms. Myocarditis is an inflammation of the heart muscle that can limit the organ’s ability to pump blood and can cause changes in heartbeat rhythms.

Pfizer did not immediately respond to a request for comment.

For all the latest headlines follow our Google News channel online or via the app.

The vaccine safety board also said another two people, including a 13-year-old, had died with possible myocarditis after taking their vaccinations. More details were needed before linking the child’s death to the vaccine, while the death of a man in his 60s was unlikely related to the vaccine, it said.

Despite the rare side effects, the vaccine safety board said the benefits of vaccination greatly outweighed the risks.

Read more:

Omicron multiplies 70 times faster than delta in human airways: Study

Pfizer set to oust AstraZeneca as top supplier of COVID-19 vaccines to poor nations

US study suggests COVID vaccines may be ineffective against omicron without boosters